Molecular mechanisms in signal transduction: new targets for the therapy of gynecologic malignancies.
Growth factor-mediated signal transduction pathways in gynecologic malignancies are summarized. Targeting critical tyrosine kinase pathways may lead to more specific anticancer regimens in gynecologic oncology. During the past 10 years significant progress in cancer treatment has been made through the discovery of potent specific and well-tolerated inhibitors of signal transduction. Improved understanding of molecules involved in signal transduction pathways will undoubtedly result in an increasing number of compounds under clinical investigation. Some of the described molecular therapeutic approaches are suitable to enrich the conventional chemotherapy.
Universitäts-Frauenklinik Freiburg i. Br.
B
B
Gabriel
D-C
DC
Fischer
D G
DG
Kieback
D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy / Q000235:genetics*; D017024:Chemotherapy, Adjuvant; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000235:genetics*; D005260:Female; D000077156:Gefitinib; D006801:Humans; D000922:Immunotoxins / Q000008:administration & dosage; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000235:genetics*; D011799:Quinazolines / Q000008:administration & dosage; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000235:genetics*; D015398:Signal Transduction / Q000187:drug effects / Q000235:genetics*; D000068878:Trastuzumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D066246:ErbB Receptors; D000077156:Gefitinib; D000922:Immunotoxins; D011799:Quinazolines; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab